Eli Lilly and Company $LLY Shares Purchased by International Private Wealth Advisors LLC

Key Points

• International Private Wealth Advisors LLC increased its stake in Eli Lilly by 40.1%, acquiring an additional 480 shares, bringing its total holdings to 1,676 shares worth approximately $1.3 million.
• Insider trading activity includes Director Jamere Jackson purchasing 200 shares and Director Gabrielle Sulzberger buying 117 shares, indicating insider confidence in the company's prospects.
• Eli Lilly recently reported $6.31 EPS for the quarter, surpassing analysts' expectations, and set a 2025 guidance of 21.750-23.000 EPS.

International Private Wealth Advisors LLC lifted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 40.1% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,676 shares of the company's stock after purchasing an additional 480 shares during the quarter. Eli Lilly and Company comprises 1.1% of International Private Wealth Advisors LLC's portfolio, making the stock its 22nd biggest holding. International Private Wealth Advisors LLC's holdings in Eli Lilly and Company were worth $1,306,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. PNC Financial Services Group Inc. boosted its holdings in shares of Eli Lilly and Company by 97.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock worth $83,669,349,000 after purchasing an additional 50,002,551 shares during the period. Vanguard Group Inc. boosted its holdings in Eli Lilly and Company by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock valued at $65,432,218,000 after acquiring an additional 4,975,395 shares during the period. GAMMA Investing LLC boosted its holdings in Eli Lilly and Company by 103,831.6% during the 1st quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after acquiring an additional 14,852,076 shares during the period. Wellington Management Group LLP boosted its holdings in Eli Lilly and Company by 0.6% during the 1st quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company's stock valued at $10,495,261,000 after acquiring an additional 81,587 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in Eli Lilly and Company by 13.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company's stock valued at $4,808,443,000 after acquiring an additional 682,203 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Daniel Skovronsky purchased 1,000 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gabrielle Sulzberger purchased 117 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the purchase, the director owned 2,703 shares of the company's stock, valued at $1,733,109.54. The trade was a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock valued at $2,894,841 in the last 90 days. 0.13% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft dropped their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a report on Monday, August 11th. DZ Bank upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. Hsbc Global Res upgraded Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a report on Wednesday, August 27th. Guggenheim lowered their target price on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a report on Wednesday, August 13th. Finally, HSBC upgraded Eli Lilly and Company from a "reduce" rating to a "hold" rating and upped their target price for the stock from $675.00 to $700.00 in a report on Wednesday, August 27th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $939.61.

Eli Lilly and Company Stock Down 1.2%

Shares of LLY traded down $9.41 during trading hours on Friday, hitting $753.52. The company had a trading volume of 7,319,147 shares, compared to its average volume of 3,181,974. The company has a market capitalization of $713.18 billion, a PE ratio of 49.25, a price-to-earnings-growth ratio of 1.05 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a one year low of $623.78 and a one year high of $939.86. The company's fifty day moving average price is $738.37 and its two-hundred day moving average price is $770.79.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period in the previous year, the company posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were paid a $1.50 dividend. The ex-dividend date was Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is 39.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.